Stratifying osteosarcoma: minimizing and maximizing therapy.
Patients who are newly diagnosed with osteosarcoma face a daunting year of medical and surgical therapy, often filled with hospitalizations and changes in lifestyle. Fortunately, the majority of patients endure this struggle to become long-term survivors. However, follow-up studies of cancer survivors are revealing the sequelae of this curative therapy. Just as disturbingly, there remains a large subset of patients for whom conventional therapy is inadequate and who succumb to disease. In this review, we propose that therapeutic strategies for osteosarcoma patients must rely on stratification of patients into risk categories, in order to minimize therapy for some, while expanding treatment for others. We then focus on two molecular targets for the treatment of patients with high-risk osteosarcoma.
Niswander
Lisa M
LM
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive,Bethesda, MD 20892, USA.
Kim
Su Young
SY
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors; D012516:Osteosarcoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D011799:Quinazolines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D017741:Survivors; D000077204:Temozolomide; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D007211:Indoles
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003606:Dacarbazine; D016023:Integrins; D011799:Quinazolines; D040262:Receptors, Vascular Endothelial Growth Factor; D000077204:Temozolomide; D042461:Vascular Endothelial Growth Factor A; C500926:cediranib; D007211:Indoles
Int J Oncol. 2008 Aug;33(2):253-9
18636145
Nat Rev Clin Oncol. 2009 Sep;6(9):507-18
19636328
J Bone Joint Surg Am. 1967 Jan;49(1):101-10
5225072
Expert Rev Anticancer Ther. 2009 Apr;9(4):511-23
19374604
J Clin Oncol. 2002 Feb 1;20(3):776-90
11821461
J Clin Oncol. 2008 Jan 20;26(3):399-405
18202416
Nat Rev Cancer. 2008 Feb;8(2):147-56
18202698
Mod Pathol. 2006 May;19(5):738-45
16528367
Nat Rev Cancer. 2010 Jan;10(1):9-22
20029421
Anticancer Res. 2007 Jan-Feb;27(1A):155-64
17352227
Eur J Cancer. 2010 Mar;46(5):901-11
20061136
J Clin Oncol. 1997 Jan;15(1):76-84
8996127
Ann Oncol. 2008 Apr;19(4):807-13
18056650
Anticancer Drugs. 2009 Nov;20(10):851-5
19826350
Cell. 1996 Aug 9;86(3):353-64
8756718
Curr Opin Oncol. 2007 Jul;19(4):341-6
17545797
Pediatr Blood Cancer. 2008 Mar;50(3):581-7
17457854
Cancer Metastasis Rev. 2005 Sep;24(3):413-23
16258729
Cancer Res. 2007 Feb 15;67(4):1645-52
17308105
Expert Rev Mol Med. 2010 Jan 18;12:e3
20078909
Future Oncol. 2009 May;5(4):421-32
19450171
J Clin Oncol. 1994 Dec;12(12):2614-20
7989936
Cell. 2006 Aug 11;126(3):489-502
16901783
BMC Genomics. 2009 Dec 23;10:625
20028558
Cell. 2002 Sep 20;110(6):673-87
12297042
Curr Oncol Rep. 2008 Jul;10(4):350-8
18778562
Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26
15459662
Clin Cancer Res. 2000 Feb;6(2):572-7
10690541
Hum Pathol. 2006 Aug;37(8):1009-14
16867863
J Bone Joint Surg Am. 1970 Apr;52(3):411-23
5269156
Int J Cancer. 2005 Dec 20;117(6):883-8
16152621
PLoS Med. 2009 Oct;6(10):e1000161
19823573
Cancer Res. 2005 May 15;65(10):4389-400
15899831
Nature. 2000 Sep 14;407(6801):249-57
11001068
Oncogene. 2009 Sep 24;28(38):3401-11
19597468